SAN DIEGO and TORONTO, Nov.  14, 2022  (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced dosing of the first patient to receive a continuous dosing regimen of the G3 formulation of luxeptinib, a potent, non-covalent oral inhibitor of BTK and FLT3, in the ongoing Phase 1a/b clinical trial in patients with relapsed or refractory (r/r) acute myeloid leukemia (AML).
Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib
Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib --  Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced dosing of the first patient to receive a continuous dosing regimen of the G3 formulation of luxeptinib, a potent, non-covalent oral inhibitor of BTK and FLT3, in the ongoing Phase 1a/b clinical trial in patients with relapsed or refractory (r/r) acute myeloid leukemia (AML).